These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3160638)

  • 21. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
    Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P
    Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental study of the treatment of uterine leiomyosarcoma in the mouse with progestogen].
    Sato Y; Tanaka K; Arakawa O; Ono M; Hirohashi T; Obata N; Takeuchi S
    Gan No Rinsho; 1988 Nov; 34(14):1979-84. PubMed ID: 2974492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medroxyprogesterone acetate binding sites in human endometrium and endometrial cancer.
    Ohno Y; Fujibayashi H; Kitagawa I; Fujimoto Y; Okada H
    Gynecol Obstet Invest; 1990; 29(3):227-31. PubMed ID: 2141586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effects of danazol and medroxyprogesterone acetate on [3H]thymidine incorporation in human endometrial cancer cells.
    Terakawa N; Ikegami H; Shimizu I; Inoue M; Tanizawa O; Matsumoto K
    J Steroid Biochem; 1988 Jul; 31(1):131-5. PubMed ID: 2969434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of medroxyprogesterone acetate on enzyme activities in human endometrial carcinoma.
    Philipson KA; Elder MG; White JO
    J Steroid Biochem; 1985 Dec; 23(6A):1059-64. PubMed ID: 2936931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.
    Kauppila A; Isotalo H; Kivinen S; Stenbäck F; Vihko R
    Int J Cancer; 1985 Feb; 35(2):157-63. PubMed ID: 3156097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estradiol and progesterone receptors in two cases of endometrial stromal sarcoma.
    Lantta M; Kahanpää K; Kärkkäinen J; Lehtovirta P; Wahlström T; Widholm O
    Gynecol Oncol; 1984 Jun; 18(2):233-9. PubMed ID: 6735266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Estrogen and progesterone receptors in corpus uteri carcinoma and their clinical significance].
    Kleine W; Fuchs A; deGregorio G; Geyer H
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):884-7. PubMed ID: 6925560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma.
    Liao BS; Twiggs LB; Leung BS; Yu WC; Potish RA; Prem KA
    Obstet Gynecol; 1986 Apr; 67(4):463-7. PubMed ID: 3960417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate.
    Grenman SE; Roberts JA; England BG; Grönroos M; Carey TE
    Gynecol Oncol; 1988 Jun; 30(2):239-50. PubMed ID: 2967231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen and progesterone receptors in uterine sarcomas.
    Sutton GP; Stehman FB; Michael H; Young PC; Ehrlich CE
    Obstet Gynecol; 1986 Nov; 68(5):709-14. PubMed ID: 3763088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
    Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
    Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells.
    Yamashita J; Horiuchi S; Kimura M; Nishimura R; Akagi M
    Jpn J Cancer Res; 1986 Feb; 77(2):177-81. PubMed ID: 3082829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.
    Blossey HC; Wander HE; Koebberling J; Nagel GA
    Cancer; 1984 Sep; 54(6 Suppl):1208-15. PubMed ID: 6088020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma.
    Creasman WT; McCarty KS; Barton TK; McCarty KS
    Obstet Gynecol; 1980 Mar; 55(3):363-70. PubMed ID: 7189047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid receptors and response of endometrial cancer to hormones in vitro.
    Grönroos M; Mäenpää J; Kangas L; Erkkola R; Paul R; Grenman S
    Ann Chir Gynaecol Suppl; 1987; 202():76-9. PubMed ID: 2959189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment.
    Lindahl B; Alm P; Fernö M; Norgren A
    Anticancer Res; 1990; 10(3):725-30. PubMed ID: 2142394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma.
    Ciuffi M; Savino L; Santini D; Buzzoni P; Scarselli G; Mazzei T
    Tumori; 1982 Jun; 68(3):217-21. PubMed ID: 6958113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex steroid receptors in endometrial cancer.
    Chambers JT
    Yale J Biol Med; 1988; 61(4):339-50. PubMed ID: 3055700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy?
    Benraad TJ; Friberg LG; Koenders AJ; Kullander S
    Acta Obstet Gynecol Scand; 1980; 59(2):155-9. PubMed ID: 7405552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.